News

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday. The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's ...

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors To Secure Counsel Before Important Deadline In Securities Class Action

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...
TipRanks on MSN22h

Altimmune Reports Promising Trial Results and Financial Growth

Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ...

Altimmune Inc (ALT) reports a robust cash reserve and significant progress in drug trials, despite ongoing financial losses ...
TipRanks on MSN13h

Altimmune price target lowered to $24 from $26 at UBS

UBS lowered the firm’s price target on Altimmune (ALT) to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial ...